Rexahn Pharmaceuticals, Inc. Submits Archexin Phase II Protocol for Ovarian Cancer to FDA
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol for the clinical study of Archexin® as a treatment of ovarian cancer to the U.S. Food and Drug Administration (FDA).